Education
About Us
Working with TipRanks
Follow Us
Cogent Biosciences (COGT)
NASDAQ:COGT
COGT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.88 - $12.61
Previous CloseN/A
Volume181.15K
Average Volume (3M)1.19M
Market Cap
$681.96M
Enterprise Value$702.59M
Total Cash (Recent Filing)$25.70M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.53
Next Earnings
May 13, 2025EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.46
Shares Outstanding113,850,090
10 Day Avg. Volume1,161,223
30 Day Avg. Volume1,194,586
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)930.20
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.58
Forecast
1Y Price Target
$16.67Price Target Upside187.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Cogent Biosciences News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsCogent presented favorable Part 1 results from the Phase 3 Peak trial, which is evaluating bezuclastinib + sunitinib in 2L GIST.
Market OpportunityBezu may be able to capture broader market share in advanced systemic mastocytosis due to its more favorable heme tox profile.
Treatment EfficacyBezuclastinib resulted in significant improvements in symptom severity as measured by Cogent's novel patient-reported outcome measurement scale.
Bears Say
Competitive LandscapeIt appears that IDRX-42 yields a greater efficacy profile than bezuclastinib + sunitinib.
Pricing TargetThe 12-month price target has been lowered to $14 from the prior $17 per share.
Safety ConcernsInvestors will scrutinize the liver toxicity profile of bezuclastinib following the disclosure of 3 total cases of Gr3 AST/ALT elevations in ISM.
---
Ownership Overview
11.78% Insiders
17.43% Mutual Funds
0.68% Other Institutional Investors
57.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
COGT FAQ
What was Cogent Biosciences’s price range in the past 12 months?
Cogent Biosciences lowest stock price was $5.88 and its highest was $12.61 in the past 12 months.
What is Cogent Biosciences’s market cap?
Cogent Biosciences’s market cap is $681.96M.
When is Cogent Biosciences’s upcoming earnings report date?
Cogent Biosciences’s upcoming earnings report date is May 13, 2025 which is in 40 days.
How were Cogent Biosciences’s earnings last quarter?
Cogent Biosciences released its earnings results on Feb 25, 2025. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.598 by -$0.012.
Is Cogent Biosciences overvalued?
According to Wall Street analysts Cogent Biosciences’s price is currently Undervalued.
Does Cogent Biosciences pay dividends?
Cogent Biosciences does not currently pay dividends.
What is Cogent Biosciences’s EPS estimate?
Cogent Biosciences’s EPS estimate is -0.58.
How many shares outstanding does Cogent Biosciences have?
Cogent Biosciences has 113,850,090 shares outstanding.
What happened to Cogent Biosciences’s price movement after its last earnings report?
Cogent Biosciences reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.598. Following the earnings report the stock price went down -6.3%.
Which hedge fund is a major shareholder of Cogent Biosciences?
Currently, no hedge funds are holding shares in COGT
---
Cogent Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.67 (187.91% Upside)
$16.67 (187.91% Upside)
Blogger Sentiment
Bullish
COGT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.86%
12-Months-Change
Fundamentals
Return on Equity
-99.54%
Trailing 12-Months
Asset Growth
4.61%
Trailing 12-Months
Company Description
Cogent Biosciences
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
---
COGT Stock 12 Month Forecast
Average Price Target
$16.67
▲(187.91% Upside)
Technical Analysis
Prothena
―
Anavex Life Sciences
―
Evolus
―
LENZ Therapeutics
―
Bicara Therapeutics Inc.
―
Best Analysts Covering COGT
1 Year
1 Year Success Rate
7/26 ratings generated profit
1 Year Average Return
-7.97%
reiterated a buy rating last month
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 26.92% of your transactions generating a profit, with an average return of -7.97% per trade.
---